Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
7,617 results
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00075881).
- Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00440726).
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: primary endpoint results, effect estimate with…
- Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis:…
- BOSTON-4Independent statistical analysis of A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bosutinib in Adult Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bosutinib in Adult Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01331291).
- Botox + FESIndependent statistical analysis of Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BOTOX® Economic Spasticity Trial (BEST): Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Economic Spasticity Trial (BEST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00549783).
- BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02230956).
- BOTOX® for the Treatment of Platysma Prominence: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® for the Treatment of Platysma Prominence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03915067).
- BOTOX® Prophylaxis in Patients With Chronic Migraine: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Prophylaxis in Patients With Chronic Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01432379).
- BotticelliIndependent statistical analysis of Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Botulin-A Toxin Instillations and Overactive Bladder: Complete Statistical AnalysisIndependent statistical analysis of Botulin-A Toxin Instillations and Overactive Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00583219).
- Botulinum Toxin A to Treat Arm Tremor: Complete Statistical AnalysisIndependent statistical analysis of Botulinum Toxin A to Treat Arm Tremor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02207946).
- Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness: Complete Statistical AnalysisIndependent statistical analysis of Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint: Complete Statistical AnalysisIndependent statistical analysis of Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access: Complete Statistical AnalysisIndependent statistical analysis of Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia: Complete Statistical AnalysisIndependent statistical analysis of Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BP MAPIndependent statistical analysis of Improving BP Control in Diverse Populations Using BP MAP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03818659).
- Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram: Complete Statistical AnalysisIndependent statistical analysis of Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Brain Stimulation and Enhancing Cognition in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Brain Stimulation and Enhancing Cognition in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03653351).
- Brain Training to Enhance Frontal Lobe Reasoning: Complete Statistical AnalysisIndependent statistical analysis of Brain Training to Enhance Frontal Lobe Reasoning: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01552473).
- BRAiN-MIndependent statistical analysis of Bringing Relief to Adolescents Naturally Using Melatonin for Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02344316).
- BrainRadioIndependent statistical analysis of Neural Signatures of Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01990313).
- BRANCHIndependent statistical analysis of Bare Metal Bifurcation Stent Clinical Trial in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00607321).
- BRAVE-EPAIndependent statistical analysis of Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02719327).
- BRAVOIndependent statistical analysis of A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO): primary endpoint results, effect estimate with…
- BRAVOIndependent statistical analysis of Buprenorphine to Improve HIV Care Engagement and Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01936857).
- Break MBIndependent statistical analysis of A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Breast Cancer Risk Biomarkers in Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of Breast Cancer Risk Biomarkers in Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01252290).
- BreastCAREIndependent statistical analysis of Breast Cancer Risk Reduction: A Patient Doctor Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01830933).
- BREEZE-AD1Independent statistical analysis of A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BretuximabIndependent statistical analysis of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment: Complete Statistical AnalysisIndependent statistical analysis of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD): Complete Statistical AnalysisIndependent statistical analysis of Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer’s Type: Complete Statistical AnalysisIndependent statistical analysis of Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BridgeIndependent statistical analysis of Maintenance of Platelet Inhibition With Cangrelor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00767507).
- BRIDGE Percutaneous Nerve Stimulation for Cesarean Delivery Pain Control: Complete Statistical AnalysisIndependent statistical analysis of BRIDGE Percutaneous Nerve Stimulation for Cesarean Delivery Pain Control: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04365465).
- Bridging the Evidence-to-practice Gap: Complete Statistical AnalysisIndependent statistical analysis of Bridging the Evidence-to-practice Gap: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03713515).
- Brief Cognitive Behavioral Therapy for Chronic Pain to Improve Functioning Among Veterans: Complete Statistical AnalysisIndependent statistical analysis of Brief Cognitive Behavioral Therapy for Chronic Pain to Improve Functioning Among Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Brief Cognitive Behavioral Therapy for Military Populations: Complete Statistical AnalysisIndependent statistical analysis of Brief Cognitive Behavioral Therapy for Military Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02038075).
- Brief Educational Video for Patients Prescribed LTBI Treatment: Complete Statistical AnalysisIndependent statistical analysis of Brief Educational Video for Patients Prescribed LTBI Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05412212).
- Brief Group Psychoeducation for Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Brief Group Psychoeducation for Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02911519).
- Brief Intervention for Justice-Involved Substance Users: Complete Statistical AnalysisIndependent statistical analysis of Brief Intervention for Justice-Involved Substance Users: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03308877).
- Brigatinib Before Brain Irradiation Trial (B3i Trial): Complete Statistical AnalysisIndependent statistical analysis of Brigatinib Before Brain Irradiation Trial (B3i Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04634110).